A randomized controlled trial on the efficacy and safety of a food ingredient, collagen hydrolysate, for improving joint comfort
Effect None
Trial Design doubleblind
Trial Length 7months
Number of Subjects 207
Gender mixed
Notes for this study:
In patients with osteoarthritis given 10g hydrolyzed collagen over six months appeared to reduce pain assessed by VAS and WOMAC, although no other parameter on WOMAC (stiffness, function, or total score) was affected by treatment relative to placebo.
Funding issues for this study:
Funded by Colnatur, the producer of the collagen provided

Safety And Efficacy Of Undenatured Type II Collagen In The Treatment Of Osteoarthritis Of The Knee: A Clinical Trial

Effect Decrease
Trial Design Cohort
Trial Length 1-6 months
Number of Subjects 52
Gender Both Genders
Age Range 45-64
Body Types Average
Notes for this study:
Supplementation of 40mg UC-II (undenatured CII) once daily for three months was able to improve symptoms of osteoarthritis as assessed by WOMAC, VAS, and Lequesne rating scales. The potency was comparable to a combination of glucosamine HCl (1,500mg) and chondroitin sulphate (1,200mg) on Lequesne and VAS, and more effective on WOMAC.

There was no placebo control used in this study and medication was relatively well tolerated.
Funding issues for this study:
Funded by InterHealth Research Center